Skip to main content
Journal cover image

Cardiovascular Toxicity of Novel HER2-Targeted Therapies in the Treatment of Breast Cancer.

Publication ,  Journal Article
Dent, SF; Morse, A; Burnette, S; Guha, A; Moore, H
Published in: Current oncology reports
August 2021

HER2-targeted therapies have led to improved clinical outcomes in early and advanced breast cancer (BC). We review the long-term cardiotoxicity of HER2-targeted therapy in early and advanced BC, our current knowledge of cardiotoxicity of novel HER2-targeted therapies, and propose a cardiac monitoring (CM) strategy for this population.Long-term data from studies with HER2-targeted therapy in the adjuvant setting have failed to demonstrate an increase in cardiotoxicity over time, and rates of cardiotoxicity seen with novel HER2 agents remain low. Despite over a decade of experience with HER2-targeted therapy, CM in clinical practice is inconsistent in patients with early BC and almost non-existent in advanced BC. Long-term follow-up of clinical trials with HER2-targeted agents in early and advanced BC has failed to demonstrate increased rates of cardiotoxicity over time, attesting to the long-term safety of this class of drugs for the majority of patients, although the long-term cardiac safety of newer HER2 agents in the non-clinical trial setting is largely unknown. We propose CM incorporating clinical history, cardiac imaging, and biomarkers.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Current oncology reports

DOI

EISSN

1534-6269

ISSN

1523-3790

Publication Date

August 2021

Volume

23

Issue

11

Start / End Page

128

Related Subject Headings

  • Receptor, erbB-2
  • Receptor, ErbB-2
  • Protein Kinase Inhibitors
  • Oncology & Carcinogenesis
  • Molecular Targeted Therapy
  • Immunoconjugates
  • Humans
  • Female
  • Clinical Trials as Topic
  • Cardiotoxicity
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Dent, S. F., Morse, A., Burnette, S., Guha, A., & Moore, H. (2021). Cardiovascular Toxicity of Novel HER2-Targeted Therapies in the Treatment of Breast Cancer. Current Oncology Reports, 23(11), 128. https://doi.org/10.1007/s11912-021-01114-x
Dent, Susan F., Amber Morse, Sarah Burnette, Avirup Guha, and Heather Moore. “Cardiovascular Toxicity of Novel HER2-Targeted Therapies in the Treatment of Breast Cancer.Current Oncology Reports 23, no. 11 (August 2021): 128. https://doi.org/10.1007/s11912-021-01114-x.
Dent SF, Morse A, Burnette S, Guha A, Moore H. Cardiovascular Toxicity of Novel HER2-Targeted Therapies in the Treatment of Breast Cancer. Current oncology reports. 2021 Aug;23(11):128.
Dent, Susan F., et al. “Cardiovascular Toxicity of Novel HER2-Targeted Therapies in the Treatment of Breast Cancer.Current Oncology Reports, vol. 23, no. 11, Aug. 2021, p. 128. Epmc, doi:10.1007/s11912-021-01114-x.
Dent SF, Morse A, Burnette S, Guha A, Moore H. Cardiovascular Toxicity of Novel HER2-Targeted Therapies in the Treatment of Breast Cancer. Current oncology reports. 2021 Aug;23(11):128.
Journal cover image

Published In

Current oncology reports

DOI

EISSN

1534-6269

ISSN

1523-3790

Publication Date

August 2021

Volume

23

Issue

11

Start / End Page

128

Related Subject Headings

  • Receptor, erbB-2
  • Receptor, ErbB-2
  • Protein Kinase Inhibitors
  • Oncology & Carcinogenesis
  • Molecular Targeted Therapy
  • Immunoconjugates
  • Humans
  • Female
  • Clinical Trials as Topic
  • Cardiotoxicity